Abstract:Lysine-specific demethylase 1 (LSD1/KDM1A) has emerged as a promising therapeutic target for treating various cancers (such as breast cancer, liver cancer, etc.) and other diseases (blood diseases, cardiovascular diseases, etc.), owing to its observed overexpression, thereby presenting significant opportunities in drug development. Since its discovery in 2004, extensive research has been conducted on LSD1 inhibitors, with notable contributions from computational approaches. This review systematically summarizes LSD1 inhibitors investigated through computer-aided drug design (CADD) technologies since 2010, showcasing a diverse range of chemical scaffolds, including phenelzine derivatives, tranylcypromine (abbreviated as TCP or 2-PCPA) derivatives, nitrogen-containing heterocyclic (pyridine, pyrimidine, azole, thieno[3,2-b]pyrrole, indole, quinoline and benzoxazole) derivatives, natural products (including sanguinarine, phenolic compounds and resveratrol derivatives, flavonoids and other natural products) and others (including thiourea compounds, Fenoldopam and Raloxifene, (4-cyanophenyl)glycine derivatives, propargylamine and benzohydrazide derivatives and inhibitors discovered through AI techniques). Computational techniques, such as virtual screening, molecular docking and 3D-QSAR models, have played a pivotal role in elucidating the interactions between these inhibitors and LSD1. Moreover, the integration of cutting-edge technologies such as artificial intelligence holds promise in facilitating the discovery of novel LSD1 inhibitors. The comprehensive insights presented in this review aim to provide valuable information for advancing further research on LSD1 inhibitors.

Optimization and Biological Evaluation of Novel 1 H -Pyrrolo[2,3- c ]pyridin Derivatives as Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives As Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Development of the Triazole-Fused Pyrimidine Derivatives As Highly Potent and Reversible Inhibitors of Histone Lysine Specific Demethylase 1 (LSD1/KDM1A)

Optimization of 5-Arylidene Barbiturates As Potent, Selective, Reversible LSD1 Inhibitors for the Treatment of Acute Promyelocytic Leukemia.

Design, synthesis and biological evaluation of novel benzofuran derivatives as potent LSD1 inhibitors

Design, Synthesis and Biological Activity of N-(3-substituted-phenyl)benzenesulfonamides As Selective and Reversible LSD1 Inhibitors

Design, Synthesis, and Structure-Activity Relationship of Novel LSD1 Inhibitors Based on Pyrimidine-Thiourea Hybrids As Potent, Orally Active Antitumor Agents.

Design, Synthesis and Biological Activity of 3-Oxoamino-benzenesulfonamides As Selective and Reversible LSD1 Inhibitors.

Structure–Activity Relationship Study of Indolin-5-yl-cyclopropanamine Derivatives as Selective Lysine Specific Demethylase 1 (LSD1) Inhibitors

Synthesis and biological evaluation of novel (E)-N’-(2, 3-dihydro-1H-inden-1-ylidene) benzohydrazides as potent LSD1 inhibitors

Design, Synthesis and Biological Activity of 4-(4-benzyloxy)phenoxypiperidines As Selective and Reversible LSD1 Inhibitors.

Molecular docking, 3D-QSAR, and molecular dynamics simulations of thieno[3,2-b]pyrrole derivatives against anticancer targets of KDM1A/LSD1

Lysine-Specific Demethylase 1 Inhibitors: A Comprehensive Review Utilizing Computer-Aided Drug Design Technologies

Structure-activity studies on N-Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation

Discovery of Natural Product-Like Spirooxindole Derivatives As Highly Potent and Selective LSD1/KDM1A Inhibitors for AML Treatment.

Promising natural lysine specific demethylase 1 inhibitors for cancer treatment: advances and outlooks

Design Two Novel Tetrahydroquinoline Derivatives Against Anticancer Target LSD1 with 3D-QSAR Model and Molecular Simulation

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

Identification of Novel Selective Lysine‐Specific Demethylase 1 (LSD1) Inhibitors Using a Pharmacophore‐Based Virtual Screening Combined with Docking

Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer

Pharmacological Inhibition of LSD1 for Cancer Treatment